David Baltimore's Scientific Legacy and the Research Bridge He Built With China

From Nobel discoveries to laboratories across China

David Baltimore, the American biologist who won the 1975 Nobel Prize in Physiology or Medicine, died this month at 87. Across China and among Chinese American researchers, tributes have focused on a contribution that reached beyond his discoveries about viruses and immunity: decades spent connecting scientists, training young researchers and helping institutions take shape.

His connections stretched from Beijing and Shanghai to Los Angeles and Boston. He returned to Chinese universities and research institutes for seminars, workshops and conversations with students. Those visits often produced practical results, including collaborations, faculty recruitment and plans for new research centers.

Baltimore helped advise the Suzhou Institute of Systems Medicine, supported Westlake University as it developed graduate programs and twice served as president of the World Life Science Conference in Beijing. His influence also traveled through dozens of Chinese trainees, some of whom remained in the United States while others returned to China to establish laboratories and programs.

His final scientific paper appeared just days before his death in the inaugural issue of the Chinese journal Immunity & Inflammation. It returned to NF kappa B, a regulator of immune activity that his laboratory helped identify. For colleagues who knew his work in China, the publication brought together two lasting commitments: understanding how cells defend the body and supporting an international community capable of pursuing difficult questions.

Baltimore's approach rested on a straightforward belief that research progresses faster when people and ideas move across borders. As China expanded its investment in biomedicine, he helped turn personal contacts into programs supporting training, basic discovery and the translation of laboratory findings into possible medical applications.

Discoveries that changed the understanding of disease

In the early 1970s, Baltimore identified reverse transcriptase, an enzyme that certain RNA viruses use to make DNA. The discovery challenged the textbook view that genetic information moved in only one direction and explained how retroviruses reproduce.

Reverse transcriptase became a central tool in molecular biology and a target for important HIV treatments. Understanding the enzyme gave researchers a way to study viruses that write their genetic information into a host's genome and develop medicines that interfere with that process. Baltimore received the Nobel Prize while still in his 30s.

His laboratory also helped identify NF kappa B, a transcription factor. Transcription factors act as switches for genes, helping determine which instructions a cell follows. NF kappa B activates genes involved in inflammation and cell survival. When its activity is poorly controlled, cells can send distress signals at the wrong time, damaging surrounding tissues.

Medicines that influence this pathway aim to reduce excessive inflammation while preserving the body's normal defenses. The challenge is to quiet a harmful response without removing the protection needed to fight infection.

Baltimore's group also discovered the genes RAG1 and RAG2, which drive a process called VDJ recombination. This genetic shuffling creates billions of different antibodies and T cell receptors, giving the immune system an enormous range of ways to recognize pathogens. Understanding these genes helped explain how adaptive immunity develops its varied defenses and why the process sometimes goes wrong.

Another strand of research examined ABL1, a tyrosine kinase, or an enzyme involved in cellular signaling. When ABL1 becomes fused with BCR in certain leukemias, the resulting signal can become overactive. Work from Baltimore's scientific circle contributed to the rationale for imatinib, the targeted medicine that transformed treatment for chronic myeloid leukemia. This approach helped shape precision oncology: selecting treatment around a specific molecular cause of cancer.

The trainees who carried his influence across the Pacific

Chinese students and postdoctoral fellows who trained with Baltimore became part of a network linking laboratories in Guangzhou, Shanghai, Beijing and Suzhou with research centers in the United States. Some became senior faculty in America. Others returned to China to build new programs.

Those relationships made it easier to share experimental methods, write papers together and connect promising researchers with places where they could develop. His role often continued after a trainee left his laboratory, through advice, introductions and discussions about scientific direction.

Cheng Genhong, an immunologist who trained with Baltimore and now leads the Suzhou Institute of Systems Medicine, credited him with helping shape the institute's strategy. Cheng also described his encouragement of young scientists to pursue ambitious questions while maintaining rigorous methods.

In his tribute, Cheng described the reach of Baltimore's engagement with Chinese research institutions:

Dr Baltimore visited China many times, with his footprints across numerous universities and research institutes.

Baltimore's mentoring included crowded lectures and smaller discussions where students could test their ideas. It also involved quieter work: listening to a research plan, sketching an experiment at a whiteboard or calling a colleague to suggest a visit for a promising scientist. For Cheng and other colleagues, such attention was central to the belief that mentorship and international exchange could open doors for young researchers.

Building institutions in Suzhou, Hangzhou and Beijing

The Suzhou Institute of Systems Medicine counts Baltimore as a founding advisor. He co chaired its scientific advisory board with Zhu Chen, the physician scientist who served as China's health minister. The institute brings together immunology, systems biology and precision medicine, reflecting an interest in research that crosses disciplinary boundaries.

Systems medicine studies how genes, proteins, cells and tissues interact, rather than examining only one molecule at a time. In cancer and immune disorders, disease can be driven by circuits of signals. Mapping those circuits can help researchers identify where treatment might change their activity.

Baltimore encouraged training that combined computation, genetic sequencing and classical biology. Institutes that followed this approach train students to write computer code, design CRISPR screens and interpret clinical data alongside laboratory experiments. CRISPR screens use gene editing tools to investigate which genes contribute to a biological process.

Westlake University in Hangzhou invited Baltimore onto its governing board as it developed a university focused on graduate education and intensive research, with international standards. His guidance supported the creation of new graduate programs and another model for organizing scientific training in China.

In Beijing, his two terms as president of the World Life Science Conference brought him into contact with young investigators and senior research leaders. Across these roles, institutional planning remained connected to direct engagement with scientists. Advisory boards, graduate programs and conference networks gave those relationships structures that could continue beyond any individual visit.

How the relationship developed over time

Baltimore's scientific work and his engagement with China unfolded against a changing international setting. Several dates help place the discoveries, cooperation and later debates about oversight in sequence:

• Early 1970s: Baltimore identified reverse transcriptase, explaining how certain RNA viruses make DNA.
• 1975: He received the Nobel Prize in Physiology or Medicine while in his 30s.
• 1979: The United States and China first signed their Science and Technology Agreement, establishing a lasting framework for scientific cooperation.
• 2018: He Jiankui's announcement of babies born after embryo gene editing in Shenzhen prompted international criticism and renewed demands for stronger oversight.
• September 2025: Baltimore died at 87. His final scientific paper had appeared days earlier in the inaugural issue of Immunity & Inflammation.

Over the five decades following his Nobel recognition, Baltimore advised new Chinese institutes, visited campuses and mentored researchers who helped shape laboratories on both sides of the Pacific. His involvement grew alongside China's scientific capacity, while the political conditions surrounding cooperation became more contested.

Open exchange amid tighter scrutiny

The U.S. China Science and Technology Agreement, first signed in 1979, has faced rounds of negotiation and delay in recent years. Washington has sought stronger protections and clearer terms for cooperation. No date for the next agreement decision was given.

Universities in the United States have also tightened disclosure rules and reviewed conflicts in response to funding agency concerns about foreign relationships that had not been declared. High profile cases at Emory University and MD Anderson illustrated the risks surrounding undisclosed funding, appointments or access to data.

For researchers, disclosure means telling an institution or funding agency about relevant outside support, positions and commitments. Accurate information allows those organizations to assess competing obligations and decide what safeguards a project needs.

Baltimore advocated open exchange and valued the participation of young scientists from many countries. Researchers who trained with him described expectations of rigor and openness consistent with international standards. Those values can operate alongside clear policies, timely disclosure and strong review of sensitive research.

Shared governance, regular audits and reciprocal sharing of data offer practical ways to build trust between institutions. As scrutiny increased, the challenge for laboratories connected through Baltimore's network was to sustain useful collaboration while meeting their responsibilities to universities, funders and research participants.

Gene editing exposed gaps in scientific oversight

In 2018, researcher He Jiankui revealed that babies had been born after he manipulated embryos in Shenzhen. The project used CRISPR to target the CCR5 gene, with the aim of conferring resistance to HIV.

The controversy centered on germline editing, which changes genetic information that can be passed to future generations. Most governments and scientific groups have said that this boundary should not be crossed without broad public agreement and clear evidence of safety. Decisions about such experiments can affect future children as well as the people directly participating in research.

Later reporting showed that a circle of people had suspected or known that He was moving toward an intervention involving human embryos. Some advised against it. Others remained silent or learned about the births only after the announcement.

The episode exposed weaknesses in institutional oversight and the scientific community's ability to regulate itself. China subsequently strengthened its rules, while international groups renewed calls for shared standards governing embryo research and clinical research using gene editing tools.

For scientists working in China or with Chinese partners, the case demonstrated the need for more than seminars and review committees. Clear laws, ethics boards with authority and professional societies able to impose sanctions are needed to enforce safety and consent requirements. The purpose is to ensure that consequential research, especially work affecting future children, receives scrutiny before decisive steps are taken.

A final paper returned to the immune system's switches

Baltimore's last scientific article returned to NF kappa B in the inaugural issue of Immunity & Inflammation. Published days before his death, it summarized understanding of the pathway and considered therapeutic strategies that might reset harmful immune activity without removing necessary defenses.

NF kappa B functions like a switchboard inside a cell. When stress signals arrive, it moves into the nucleus, where genetic instructions are stored, and activates genes that begin an inflammatory response. When the trigger fades, that response normally shuts down.

Persistent activation can contribute to autoimmune disease or cancer. Autoimmune disease occurs when immune activity damages the body's own tissues. Researchers studying this pathway want to restore control over those signals while retaining the immune functions that protect health.

Publication in a Chinese journal carried personal as well as scientific meaning for colleagues who had worked with Baltimore there. It connected a longstanding research interest with the community he had supported through university visits, classroom discussions and continued attention to former trainees.

Alice Huang and a shared commitment to scientific freedom

Baltimore also had a family connection to China through his wife, virologist Alice S. Huang, who was born in Nanchang. Huang became a leader in American science policy and education and served as president of the American Association for the Advancement of Science.

Her early research on RNA viruses at the Salk Institute and later at Harvard and MIT intersected with the period when reverse transcriptase was being defined. Her career developed alongside debates about the scientific culture needed to support discovery.

Huang has argued that passion, creativity and freedom are essential to scientific progress. She has promoted international collaboration and the advancement of women and minorities in science. She and Baltimore often shared an advocacy for curiosity and open inquiry.

These concerns found an audience as Chinese laboratories expanded. Building strong research programs required attention to people as well as equipment: whether young scientists could ask questions, pursue bold ideas and work in an environment that supported them. Huang's personal history and professional commitments added another dimension to the couple's engagement with China.

What remains in laboratories and training programs

Baltimore's legacy in China rests on connected contributions to discovery, mentorship and institutions. His research and that of his trainees clarified viral replication, immune control and cancer signaling. Those ideas now support diagnostics and therapies in Chinese hospitals.

His former trainees became mentors themselves, establishing laboratories that combine basic research with clinical science and maintaining relationships with collaborators overseas. Methods and expectations could therefore travel beyond the people who worked directly with him.

In Suzhou, Hangzhou and Beijing, his involvement helped shape advisory structures, graduate education and conference networks. Such institutions give scientific relationships a longer life, allowing future students to benefit from programs established before they arrived.

For young researchers, his example joined demanding scientific standards with a willingness to hear ideas from elsewhere. He traveled because he enjoyed new questions and regarded science as a shared project. China's rapidly growing research community made room for that exchange, while its continued development will require transparency, stronger peer review and international training even as political conditions make cooperation more difficult.

Key Points

• David Baltimore died in September 2025 at 87 after decades of scientific discovery, mentoring and engagement with China.
• His contributions included reverse transcriptase, NF kappa B, RAG1 and RAG2, and research informing targeted treatment for leukemia.
• Chinese trainees built careers in both countries, sustaining networks for shared methods, research and mentorship.
• He advised the Suzhou Institute of Systems Medicine, served on Westlake University's governing board and twice led the World Life Science Conference in Beijing.
• His final scientific paper appeared in the Chinese journal Immunity & Inflammation days before his death.
• Closer scrutiny of international research and the He Jiankui controversy placed greater demands on disclosure, ethics review and accountability.
• Alice S. Huang's work and advocacy connected international cooperation with scientific freedom and opportunities for women and minorities.